Survodutide vs retatrutide: the two glucagon drugs compared

The receptor almost nobody else uses

Semaglutide hits one receptor: GLP-1. Tirzepatide hits two: GLP-1 and GIP. Survodutide and retatrutide both take a different route. Instead of (or in addition to) GIP, they add glucagon — a receptor that sits mainly in the liver and, when activated, pushes it to burn fatty acids directly. That raises resting energy expenditure, meaning the body burns more fuel at baseline, not just when you eat less. Nothing in the semaglutide or tirzepatide mechanism does this.

Survodutide is a dual agonist: GLP-1 plus glucagon, full stop. Retatrutide keeps that same glucagon receptor and adds GIP on top, making it a triple agonist. That single addition is the entire structural difference between the two drugs, which makes them an unusually clean comparison for isolating what GIP actually contributes once glucagon is already in the mix.

Weight loss: retatrutide's GIP addition shows up clearly

SYNCHRONIZE-1 enrolled 725 adults and ran 76 weeks. At the top 6mg dose, survodutide produced 16.6% mean weight loss. TRIUMPH-1 enrolled 2,339 adults and ran 80 weeks; at the 12mg dose, retatrutide produced 28.3%, or roughly 71.2 lbs on average. In the subgroup with BMI ≥35 followed to 104 weeks, that number reached 30.3%.

A roughly 12-point gap on the same underlying glucagon mechanism is a large effect for one additional receptor to produce. Some of that gap is trial design — TRIUMPH-1 ran slightly longer and enrolled a larger population — but the size of the difference points to GIP doing real work here, not just marginal amplification. That tracks with what GIP does in tirzepatide: it amplifies the effect of whatever it is paired with, whether that is a lone GLP-1 receptor or a GLP-1-plus-glucagon combination.

Liver fat: both drugs move it, retatrutide moves it further

This is where the shared glucagon mechanism shows up most clearly. Survodutide reduced liver fat by 63% and visceral fat by 34%, both measured directly by MRI in SYNCHRONIZE-1 — strong enough that the FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic-associated steatohepatitis) in September 2024. Retatrutide's 2024 Phase 2 substudy went further: an 86% reduction in liver fat, with 93% of participants returning to normal levels and 72% of prediabetic participants normalizing blood sugar.

Neither semaglutide nor tirzepatide has posted liver fat numbers close to these. That is the clearest evidence that the glucagon receptor itself, not just GLP-1 or GIP, is doing distinct work on hepatic fat — and it is the reason both of these drugs are being watched closely for a MASH indication regardless of how their weight-loss numbers eventually settle against tirzepatide.

Tolerability: a real cost for the extra receptor

Adding receptors tends to add side effects, and that pattern holds here. Survodutide's Phase 2 program saw roughly 8% of participants discontinue at the highest doses from GI adverse events, despite a four-step titration protocol designed to manage this. Retatrutide's GI adverse event rates run higher still than tirzepatide's or semaglutide's at comparable doses, alongside a mild heart rate increase already observed in Phase 2. Neither drug has shown new organ-level toxicity signals, but neither has years of real-world exposure either — both are still inside their respective trial windows.

Neither is available — and they are not on the same clock

Survodutide's path to filing depends on its cardiovascular outcomes trial reading out clean, which puts a realistic filing sometime after that 2026 readout. Retatrutide is further along in the sense that Eli Lilly has a filing date in view, but that still points to a decision in late 2027 at the earliest. Both timelines are estimates, not commitments, and either could slip.

What this means if you need treatment now

Tirzepatide is the only one of the three drugs discussed here that is actually FDA-approved and accessible today. If retatrutide's Phase 3 data holds through review, it will likely outperform tirzepatide on weight loss; survodutide may carve out a distinct role for liver disease specifically. Neither of those futures changes what is available right now. See the current best GLP-1 programs for what you can actually start on today, and revisit survodutide vs tirzepatide or retatrutide vs tirzepatide for how each newer drug stacks up against what is already on the market.